Zebrafish behavioral profiling identifies multitarget antipsychotic-like compounds

Nature Chemical Biology

Volumn 12, Issue 7, 2016, Pages 559-566

  Bruni, Giancarlo ^a,b   Rennekamp, Andrew J ^a,c,d   Velenich, Andrea ^b   McCarroll, Matthew ^e   Gendelev, Leo ^e   Fertsch, Ethan ^e   Taylor, Jack ^e   Lakhani, Parth ^e   Lensen, Dennis ^b   Evron, Tama ^b   Lorello, Paul J ^a,f   Huang, Xi Ping ^g,h   Kolczewski, Sabine ⁱ   Carey, Galen ^b   Caldarone, Barbara J ^a,f   Prinssen, Eric ⁱ   Roth, Bryan L ^g,h   Keiser, Michael J ^e   Peterson, Randall T ^a,c,d   Kokel, David ^e  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Teleos Therapeutics   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF NORTH CAROLINA   (United States)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; BROMPERIDOL; CLOZAPINE; DULOXETINE; FINAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSAY; CATALEPSY; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG MEGADOSE; EXPERIMENTAL HYPERACTIVITY; LOW DRUG DOSE; MOUSE; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PSYCHOSIS; ZEBRA FISH; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; LARVA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; LARVA; MICE; MOLECULAR STRUCTURE; ZEBRAFISH;

EID: 84973137464     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.2097     Document Type: Article

References (52)

1. Roth, B.L., Sheffler, D.J., Kroeze, W.K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3, 353-359 (2004).
2. Kokel, D., Peterson, R.T. Chemobehavioural phenomics and behaviour-based psychiatric drug discovery in the zebrafish. Brief. Funct. Genomics Proteomics 7, 483-490 (2008).
3. Besnard, J. et al. Automated design of ligands to polypharmacological profiles. Nature 492, 215-220 (2012).
4. Paul, S.M. et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat. Rev. Drug Discov. 9, 203-214 (2010).
5. López-Munõz, F., Alamo, C. The consolidation of neuroleptic therapy: Janssen, the discovery of haloperidol and its introduction into clinical practice. Brain Res. Bull. 79, 130-141 (2009).
6. Hippius, H. The history of clozapine. Psychopharmacology (Berl.) 99 (suppl. ), S3-S5 (1989).
7. Conn, P.J., Roth, B.L. Opportunities and challenges of psychiatric drug discovery: roles for scientists in academic, industry, and government settings. Neuropsychopharmacology 33, 2048-2060 (2008).
8. World Health Organization. WHO Model List of Essential Medicines: 18th List, April 2013 (WHO, 2013).
9. Meltzer, H.Y. An overview of the mechanism of action of clozapine. J. Clin. Psychiatry 55 (suppl. B): 47-52 (1994).
10. Lieberman, J.A. et al. The effects of clozapine on tardive dyskinesia. Br. J. Psychiatry 158, 503-510 (1991).
11. Lieberman, J.A. et al. Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs. J. Clin. Psychiatry 49, 271-277 (1988).
12. Hyman, S.E. Revolution stalled. Sci. Transl. Med. 4, 155-11 (2012).
13. Wolman, M.A., Jain, R.A., Liss, L., Granato, M. Chemical modulation of memory formation in larval zebrafish. Proc. Natl. Acad. Sci. USA 108, 15468-15473 (2011).
14. Baraban, S.C., Dinday, M.T., Hortopan, G.A. Drug screening in Scn1a zebrafish mutant identifies clemizole as a potential Dravet syndrome treatment. Nat. Commun. 4, 2410 (2013).
15. Bencan, Z., Sledge, D., Levin, E.D. Buspirone, chlordiazepoxide and diazepam effects in a zebrafish model of anxiety. Pharmacol. Biochem. Behav. 94, 75-80 (2009).
16. López-Patinõ, M.A., Yu, L., Cabral, H., Zhdanova, I.V. Anxiogenic effects of cocaine withdrawal in zebrafish. Physiol. Behav. 93, 160-171 (2008).
17. Egan, R.J. et al. Understanding behavioral and physiological phenotypes of stress and anxiety in zebrafish. Behav. Brain Res. 205, 38-44 (2009).
18. Giacomini, N.J., Rose, B., Kobayashi, K., Guo, S. Antipsychotics produce locomotor impairment in larval zebrafish. Neurotoxicol. Teratol. 28, 245-250 (2006).
19. Rihel, J. et al. Zebrafish behavioral profiling links drugs to biological targets and rest/wake regulation. Science 327, 348-351 (2010).
20. Kokel, D. et al. Rapid behavior-based identification of neuroactive small molecules in the zebrafish. Nat. Chem. Biol. 6, 231-237 (2010).
21. Kokel, D. et al. Photochemical activation of TRPA1 channels in neurons and animals. Nat. Chem. Biol. 9, 257-263 (2013).
22. Bymaster, F.P. et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25, 871-880 (2001).
23. Altschul, S.F., Gish, W., Miller, W., Myers, E.W., Lipman, D.J. Basic local alignment search tool. J. Mol. Biol. 215, 403-410 (1990).
24. Boulay, D. et al. Haloperidol-induced catalepsy is absent in dopamine D(2), but maintained in dopamine D(3) receptor knock-out mice. Eur. J. Pharmacol. 391, 63-73 (2000).
25. Dubinsky, B. et al. Bromperidol, a new butyrophenone neuroleptic: a review. Psychopharmacology (Berl.) 78, 1-7 (1982).
26. Lecrubier, Y. A partial D3 receptor agonist in schizophrenia. Eur. Neuropsychopharmacol. 13, S167-S168 (2003).
27. Peroutka, S.J., Synder, S.H. Relationship of neuroleptic drug effects at brain dopamine, serotonin, ?-adrenergic, and histamine receptors to clinical potency. Am. J. Psychiatry 137, 1518-1522 (1980).
28. Keiser, M.J. et al. Relating protein pharmacology by ligand chemistry. Nat. Biotechnol. 25, 197-206 (2007).
29. Lounkine, E. et al. Large-scale prediction and testing of drug activity on side-effect targets. Nature 486, 361-367 (2012).
30. Rennekamp, A.J. et al. ?1 receptor ligands control a switch between passive and active threat responses. Nat. Chem. Biol. doi:10.1038/nchembiol.2089 (2016).
31. Hayashi, T., Su, T. The sigma receptor: evolution of the concept in neuropsychopharmacology. Curr. Neuropharmacol. 3, 267-280 (2005).
32. Jentsch, J.D., Roth, R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20, 201-225 (1999).
33. Gleason, S.D., Shannon, H.E. Blockade of phencyclidine-induced hyperlocomotion by olanzapine, clozapine and serotonin receptor subtype selective antagonists in mice. Psychopharmacology (Berl.) 129, 79-84 (1997).
34. Freed, W.J., Bing, L.A., Wyatt, R.J. Effects of neuroleptics on phencyclidine (PCP)-induced locomotor stimulation in mice. Neuropharmacology 23, 2A, 175-181 (1984).
35. Porsolt, R.D., Moser, P.C., Castagné, V. Behavioral indices in antipsychotic drug discovery. J. Pharmacol. Exp. Ther. 333, 632-638 (2010).
36. Castagné, V., Moser, P.C., Porsolt, R.D. Preclinical behavioral models for predicting antipsychotic activity. Adv. Pharmacol. 57, 381-418 (2009).
37. Hoffman, D.C., Donovan, H. Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology (Berl.) 120, 128-133 (1995).
38. Irwin, S. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia 13, 222-257 (1968).
39. Houle, D., Govindaraju, D.R., Omholt, S. Phenomics: the next challenge. Nat. Rev. Genet. 11, 855-866 (2010).
40. Edgar, R.C. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26, 2460-2461 (2010).
41. Lamb, J. et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313, 1929-1935 (2006).
42. Gunsalus, K.C., Yueh, W.-C., MacMenamin, P., Piano, F. RNAiDB and PhenoBlast: web tools for genome-wide phenotypic mapping projects. Nucleic Acids Res. 32, D406-D410 (2004).
43. Jin, K. et al. PhenoM: a database of morphological phenotypes caused by mutation of essential genes in Saccharomyces cerevisiae. Nucleic Acids Res. 40, D687-D694 (2012).
44. Kokel, D., Rennekamp, A.J., Shah, A.H., Liebel, U., Peterson, R.T. Behavioral barcoding in the cloud: embracing data-intensive digital phenotyping in neuropharmacology. Trends Biotechnol. 30, 421-425 (2012).
45. Ahrens, M.B. et al. Brain-wide neuronal dynamics during motor adaptation in zebrafish. Nature 485, 471-477 (2012).
46. Pardo-Martin, C. et al. High-throughput in vivo vertebrate screening. Nat. Methods 7, 634-636 (2010).
47. Howe, K. et al. The zebrafish reference genome sequence and its relationship to the human genome. Nature 496, 498-503 (2013).
48. Vardy, E. et al. Single amino acid variation underlies species-specific sensitivity to amphibian skin-derived opioid-like peptides. Chem. Biol. 22, 764-775 (2015).
49. McGonigle, P. Animal models of CNS disorders. Biochem. Pharmacol. 87, 140-149 (2014).
50. Arana, G.W. An overview of side effects caused by typical antipsychotics. J. Clin. Psychiatry 61 (suppl. 8), 5-11 (2000).
51. Pangalos, M.N., Schechter, L.E., Hurko, O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Nat. Rev. Drug Discov. 6, 521-532 (2007).
52. Landrum, G. RDKit: Open-Source Cheminformatics http://www.rdkit.org (GitHub and SourceForge, accessed January 2015).